Scienture Holdings Inc (SCNX)

$0.39 -0.01 (-2.33%)
Market Cap 16.37M
Revenue (ttm) 430,000.00
Net Income (ttm) -41.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9,653.49%
Debt to Equity Ratio 0.01
Volume 319,800
Avg Vol 3,651,432
Day's Range N/A - N/A
Shares Out 40.63M
Stochastic %K 13%
Beta 3.32
Analysts Strong Sell
Price Target $1.50

Company Profile

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dih...

Industry: Pharmaceutical Retailers
Sector: Healthcare
Phone: 631) 670-6039
Address:
20 Austin Boulevard, Commack, United States
Ottersberger
Ottersberger May. 18 at 7:43 PM
$SCNX no easy way to go
0 · Reply
Ottersberger
Ottersberger May. 18 at 4:26 PM
$SCNX
0 · Reply
Marketmoverjoe
Marketmoverjoe May. 18 at 3:41 PM
$SCNX projected 5 mill this year and 56k rev. Ya, they're trying to get you to sell
0 · Reply
Ottersberger
Ottersberger May. 18 at 3:17 PM
$SCNX no confidence in the market
0 · Reply
focafoca99
focafoca99 May. 18 at 1:08 PM
$SCNX says Q1 2026 revenue surged 449% to $56 k and gross margin expanded to 95.6% after strong Arbli orders.
2 · Reply
BinaryLogic
BinaryLogic May. 16 at 4:07 PM
$SCNX Here (attached) is the latest 10Q. The Company has not shown material growth yet from Arbli (Sep-2025 launch); however, the setup here remains appealing (IMO). Rezenopy launch is scheduled for Q2, the Company just secured $11M in additional financing, and plans to become profitable in 2027. Quarterly cash burn of $(3)M approximately with $14.5M available liquidity takes them to 2H-2027. Rezenopy + Arbli in the interim must generate quarterly revenue appx $3.0-5.0M to achieve profitability ($12-20M annualized), while further developing the balance of its assets $70-80M book value attributed. I have done the math here multiple times: 10-15% market penetration on $400M equates to $40-60M annualized and P/S 2-4 $80-240M valuation. The Company needs to execute - the GM is amazing, but need to generate sales from the collaborations they have developed. Execution equates to multiplier upside here (IMO), intermediate term. https://www.sec.gov/ix?doc=/Archives/edgar/data/0001382574/000149315226023862/form10-q.htm#a_003
2 · Reply
BEATWALLSTREET
BEATWALLSTREET May. 16 at 3:06 PM
$SCNX That was their last attempt to scare retail into dumping their shares by making the earnings look terrible. The market sentiment has already shifted toward small caps, and at this point nothing is stopping the momentum to the upside. I'll sell my 300k shares at 5 sometimes this year. Mark it!
1 · Reply
Ottersberger
Ottersberger May. 16 at 7:32 AM
$SCNX The company recorded a loss of \(-\$0.08\) per share against expected losses of \(-\$0.23\), beating consensus EPS estimates. Is the only positive news in the q1
0 · Reply
Omar_w
Omar_w May. 16 at 1:26 AM
$SCNX The company reported $56.325 thousand in sales this quarter !!!
2 · Reply
Ottersberger
Ottersberger May. 15 at 3:53 PM
$SCNX huge wall at .44 - this has to be beaten down
1 · Reply
Latest News on SCNX
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion

May 18, 2026, 8:38 AM EDT - 22 hours ago

SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion

Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline

May 7, 2026, 8:05 AM EDT - 11 days ago

Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline

Scienture announces third patent granted for Arbli

2026-05-07T03:50:06.000Z - 12 days ago

Scienture announces third patent granted for Arbli

SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

May 6, 2026, 8:05 AM EDT - 12 days ago

SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

Scienture granted 180-day extension to meet Nasdaq minimum bid price

2026-04-15T13:37:53.000Z - 4 weeks ago

Scienture granted 180-day extension to meet Nasdaq minimum bid price

SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update

Mar 30, 2026, 8:07 AM EDT - 7 weeks ago

SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update

Why Is Scienture Holdings Stock (SCNX) Up Today?

2026-03-11T13:15:15.000Z - 2 months ago

Why Is Scienture Holdings Stock (SCNX) Up Today?

Scienture formalized multiple GPO agreements for Rezenopy

2026-03-11T12:16:19.000Z - 2 months ago

Scienture formalized multiple GPO agreements for Rezenopy

SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions

Mar 11, 2026, 8:05 AM EDT - 2 months ago

SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions

Scienture initiated with a Buy at Maxim

2026-02-24T13:33:22.000Z - 2 months ago

Scienture initiated with a Buy at Maxim

Scienture initiated with a Buy at Maxim

2026-02-24T13:27:59.000Z - 2 months ago

Scienture initiated with a Buy at Maxim

Scienture provides commercial update on Arbli

2026-02-03T13:11:18.000Z - 3 months ago

Scienture provides commercial update on Arbli

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Feb 3, 2026, 8:05 AM EST - 3 months ago

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Scienture announces USPTO issues patent covering REZENOPY Nasal Spray

2026-01-14T13:10:22.000Z - 4 months ago

Scienture announces USPTO issues patent covering REZENOPY Nasal Spray

SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment

Jan 14, 2026, 8:05 AM EST - 4 months ago

SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment

Scienture provides update on commercial launch of REZENOPY

2025-12-22T13:15:28.000Z - 5 months ago

Scienture provides update on commercial launch of REZENOPY

SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

Dec 22, 2025, 8:05 AM EST - 5 months ago

SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

Scienture, BlinkRx announce strategic collaboration to expand access to Arbli

2025-12-10T13:20:49.000Z - 5 months ago

Scienture, BlinkRx announce strategic collaboration to expand access to Arbli

SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Dec 10, 2025, 8:05 AM EST - 5 months ago

SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025

Dec 2, 2025, 8:05 AM EST - 5 months ago

SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025

Scienture reports Q3 EPS (19c) vs. ($1.34) last year

2025-11-13T13:15:24.000Z - 6 months ago

Scienture reports Q3 EPS (19c) vs. ($1.34) last year

SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update

Nov 13, 2025, 8:05 AM EST - 6 months ago

SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update

Scienture announces addition of Arbli to formularies of national health plans

2025-11-04T13:30:45.000Z - 6 months ago

Scienture announces addition of Arbli to formularies of national health plans

SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans

Nov 4, 2025, 8:05 AM EST - 6 months ago

SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans

Why Did Scienture Stock (SCNX) Soar 45% Today?

2025-10-23T13:06:05.000Z - 7 months ago

Why Did Scienture Stock (SCNX) Soar 45% Today?

Scienture starts commercial sales, fulfillment of first orders of Arbli

2025-10-23T12:26:28.000Z - 7 months ago

Scienture starts commercial sales, fulfillment of first orders of Arbli

SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

Oct 23, 2025, 8:05 AM EDT - 7 months ago

SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

Scienture’s Arbli is commercially available through wholesalers nationwide

2025-10-16T13:06:15.000Z - 7 months ago

Scienture’s Arbli is commercially available through wholesalers nationwide

SCIENTURE'S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

Oct 16, 2025, 9:00 AM EDT - 7 months ago

SCIENTURE'S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

Wellgistics Health Announces Executive Management and Board Changes

Oct 13, 2025, 8:00 AM EDT - 7 months ago

Wellgistics Health Announces Executive Management and Board Changes

WGRX

Scienture announces repayment, conversion of outstanding debentures

2025-10-08T13:15:30.000Z - 7 months ago

Scienture announces repayment, conversion of outstanding debentures

Scienture secures multiple commercial GPO agreements for Arbli

2025-10-01T13:06:39.000Z - 8 months ago

Scienture secures multiple commercial GPO agreements for Arbli

Scienture secures multiple commercial GPO agreements for Arbli

2025-10-01T13:06:33.000Z - 8 months ago

Scienture secures multiple commercial GPO agreements for Arbli

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Sep 16, 2025, 8:05 AM EDT - 8 months ago

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

Aug 14, 2025, 9:00 AM EDT - 9 months ago

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

Aug 13, 2025, 8:05 AM EDT - 9 months ago

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Jul 24, 2025, 5:12 PM EDT - 10 months ago

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Jul 16, 2025, 8:15 AM EDT - 10 months ago

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Scienture Holdings Announces Cancelation of ELOC

Jun 17, 2025, 8:05 AM EDT - 11 months ago

Scienture Holdings Announces Cancelation of ELOC

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

May 28, 2025, 7:45 AM EDT - 1 year ago

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

WGRX

SCIENTURE Announces Executive Leadership Transition

May 22, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE Announces Executive Leadership Transition

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

May 19, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

Apr 22, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Apr 8, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

Apr 3, 2025, 8:26 AM EDT - 1 year ago

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Mar 25, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

Mar 19, 2025, 8:05 AM EDT - 1 year ago

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

Mar 18, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Mar 6, 2025, 7:40 AM EST - 1 year ago

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Jan 21, 2025, 8:05 AM EST - 1 year ago

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Dec 17, 2024, 8:05 AM EST - 1 year ago

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

Dec 10, 2024, 8:05 AM EST - 1 year ago

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

Sep 24, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

Sep 20, 2024, 11:59 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

Aug 5, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

Jul 26, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

TRxADE Health, Inc. Announces Special Cash Dividend

Jul 9, 2024, 8:05 AM EDT - 2 years ago

TRxADE Health, Inc. Announces Special Cash Dividend

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

May 29, 2024, 4:05 PM EDT - 2 years ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Apr 23, 2024, 4:05 PM EDT - 2 years ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Trxade health, Inc files its 3Q 10Q

Jan 17, 2024, 9:07 AM EST - 2 years ago

Trxade health, Inc files its 3Q 10Q

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

Nov 29, 2023, 6:13 PM EST - 2 years ago

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Oct 17, 2023, 8:05 AM EDT - 2 years ago

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Oct 12, 2023, 8:05 AM EDT - 2 years ago

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

Oct 4, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.

Sep 7, 2023, 9:00 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods Market

Sep 6, 2023, 9:45 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods Market

Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand

Aug 24, 2023, 8:05 AM EDT - 2 years ago

Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand

Superlatus, Newly Merged with TRxADE HEALTH, Agrees to Acquire The Urgent Company, Inc. and its portfolio of Consumer Brands from Perfect Day, Inc.

Aug 22, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Newly Merged with TRxADE HEALTH, Agrees to Acquire The Urgent Company, Inc. and its portfolio of Consumer Brands from Perfect Day, Inc.

Ottersberger
Ottersberger May. 18 at 7:43 PM
$SCNX no easy way to go
0 · Reply
Ottersberger
Ottersberger May. 18 at 4:26 PM
$SCNX
0 · Reply
Marketmoverjoe
Marketmoverjoe May. 18 at 3:41 PM
$SCNX projected 5 mill this year and 56k rev. Ya, they're trying to get you to sell
0 · Reply
Ottersberger
Ottersberger May. 18 at 3:17 PM
$SCNX no confidence in the market
0 · Reply
focafoca99
focafoca99 May. 18 at 1:08 PM
$SCNX says Q1 2026 revenue surged 449% to $56 k and gross margin expanded to 95.6% after strong Arbli orders.
2 · Reply
BinaryLogic
BinaryLogic May. 16 at 4:07 PM
$SCNX Here (attached) is the latest 10Q. The Company has not shown material growth yet from Arbli (Sep-2025 launch); however, the setup here remains appealing (IMO). Rezenopy launch is scheduled for Q2, the Company just secured $11M in additional financing, and plans to become profitable in 2027. Quarterly cash burn of $(3)M approximately with $14.5M available liquidity takes them to 2H-2027. Rezenopy + Arbli in the interim must generate quarterly revenue appx $3.0-5.0M to achieve profitability ($12-20M annualized), while further developing the balance of its assets $70-80M book value attributed. I have done the math here multiple times: 10-15% market penetration on $400M equates to $40-60M annualized and P/S 2-4 $80-240M valuation. The Company needs to execute - the GM is amazing, but need to generate sales from the collaborations they have developed. Execution equates to multiplier upside here (IMO), intermediate term. https://www.sec.gov/ix?doc=/Archives/edgar/data/0001382574/000149315226023862/form10-q.htm#a_003
2 · Reply
BEATWALLSTREET
BEATWALLSTREET May. 16 at 3:06 PM
$SCNX That was their last attempt to scare retail into dumping their shares by making the earnings look terrible. The market sentiment has already shifted toward small caps, and at this point nothing is stopping the momentum to the upside. I'll sell my 300k shares at 5 sometimes this year. Mark it!
1 · Reply
Ottersberger
Ottersberger May. 16 at 7:32 AM
$SCNX The company recorded a loss of \(-\$0.08\) per share against expected losses of \(-\$0.23\), beating consensus EPS estimates. Is the only positive news in the q1
0 · Reply
Omar_w
Omar_w May. 16 at 1:26 AM
$SCNX The company reported $56.325 thousand in sales this quarter !!!
2 · Reply
Ottersberger
Ottersberger May. 15 at 3:53 PM
$SCNX huge wall at .44 - this has to be beaten down
1 · Reply
Jawick
Jawick May. 15 at 1:28 PM
$SCNX if this launch in June for this new product why shouldn't this stock hit $50
1 · Reply
Ottersberger
Ottersberger May. 14 at 6:30 PM
$SCNX next wall is at .47
0 · Reply
khaliddaman
khaliddaman May. 14 at 4:24 PM
$SCNX 🔥
0 · Reply
Ottersberger
Ottersberger May. 14 at 4:08 PM
$SCNX amen
0 · Reply
LORAXX
LORAXX May. 14 at 3:53 PM
$SCNX Start of the rise into the June launch of Rezenopy has begun. Stupid cheap. See you at $3.00+
0 · Reply
Optimistgermany
Optimistgermany May. 14 at 6:14 AM
$SCNX Launch June that is good to know…time to buy few more shares👍
1 · Reply
LORAXX
LORAXX May. 13 at 6:56 PM
$SCNX Grab all you can. When they announce the launch of Rezenopy in June, it will go bonkers. I also believe the ER will be filled with higher than expected numbers for Arbli. GLTA
0 · Reply
Ottersberger
Ottersberger May. 13 at 6:36 PM
$SCNX let’s go…the wall is fallen
0 · Reply
JackCampbell
JackCampbell May. 13 at 3:28 PM
$SCNX the recent $11M non-dilutive funds clearly signal that the investor has much confidence in SCNX and this a few weeks before earnings will be released is a massive SIGN! They´ll for sure had some deeper insight on how the company is commercially progressing!
1 · Reply
Optimistgermany
Optimistgermany May. 13 at 12:43 PM
$SCNX now 16….👍👍
0 · Reply
Supremebeing24
Supremebeing24 May. 13 at 8:37 AM
$SCNX cuntish stock. Nothing to show for months on end ffs
0 · Reply
Ottersberger
Ottersberger May. 12 at 7:58 PM
$SCNX can you 🫵🏻 pls delete you 10k Wall at 0.41 thx in advance
0 · Reply